Reverse Payments by Drug Companies: The Supreme Court Declines to Adopt a Bright-Line Test

by Thomas Carey and Nancy Chiu Wilker Ph.D. Excerpt: The Federal Trade Commission has long opposed "reverse payments," the practice by which a pioneer drug company selling a brand-name drug pays a generic drug company to not enter the market. These payments arise in connection with the...